Fifteen RCTs were included in the meta-analysis (n=7,956 patients). Sample sizes ranged from 81 to 1,369 patients. Publication bias was reported to be absent. Summary incidence of all-grade VTE (6 RCTs, n=2,279) was 11.9% (95% CI, 6.8,19.9). Heterogeneity was not reported. The summary incidence of high-grade VTE (13 RCTs, n=3795) was 6.3% (95% CI, 4.8,8.3) and statistically significant heterogeneity was reported (Q statistic=46.74, p<0.001, I squared=74.33). The summary RR of VTE (15 RCTs, n=7,956) for bevacizumab versus control was 1.33 (95% CI, 1.13, 1.56; p<0.001). The summary RR of all-grade VTE (6 RCTs, n=2,279) for bevacizumab versus control was 1.29 (95% CI, 1.03,1.63; p<0.001). The summary RR of high-grade VTE (13 RCTs, n=3,795) was 1.38 (95% CI 1.12, 1.70; p=0.002). Both high dose (5mg/kg per week) and low dose (2.5mg/kg per week) bevacizumab were associated with a statistically significant increase in the risk of VTE (RR, 1.31, 95% CI 1.02,1.68; p=0.4 and RR, 1.31, 95% CI 1.08, 1.60; p=0.007 respectively) .The incidences and RR of both all-grade VTE and high-grade VTE with bevacizumab were found to vary among the different types of tumour, with the highest RR found in colorectal cancer and the lowest in renal cell cancer.